hARP6: A Potential Drug Target and Biomarker (G64431)

Target Name: ACTR6

NCBI ID: G64431

hARP6: A Potential Drug Target and Biomarker

Harmonized Animal Research (HARP)6, also known as hARP6, is a protein that is expressed in various tissues of the human body. HARP6 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Potential Drug Target

HARP6 has been shown to play a role in several cellular processes that are associated with the development and progression of various diseases. One of the most significant functions of HARP6 is its role in the regulation of cell adhesion. HARP6 is a component of the tight junction, which is a critical barrier that helps to maintain the integrity of the endothelial cell layer. In cancer, the regulation of cell adhesion is often disrupted, leading to the development of a more invasive and migratory phenotype. Therefore, targeting HARP6 with drugs that can modulate its activity could be a promising strategy for cancer treatment.

Potential Biomarker

HARP6 has also been shown to be a potential biomarker for several diseases. For example, HARP6 has been shown to be overexpressed in various tissues of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, HARP6 has been shown to be involved in the regulation of neurotransmitter signaling, which is critical for the function of neurons. Therefore, targeting HARP6 with drugs that can modulate its activity could be a promising strategy for the treatment of neurodegenerative diseases.

HARP6 as a Target for Drug Development

Given the potential benefits of targeting HARP6 with drugs, there is a growing interest in the development of small molecules that can modulate its activity. HARP6 is a transmembrane protein, which means that it spans the cell membrane and is involved in various cellular processes. Therefore, small molecules that can interact with HARP6 on the cell membrane could be a promising strategy for drug development.

One of the most promising small molecules that can interact with HARP6 is a class of drugs called inhibitors of protein-protein interactions (PPIs). PPIs are a type of drug that can interact with a specific protein and prevent it from interacting with other proteins. This class of drugs has been shown to be effective in modulating the activity of various proteins, including HARP6.

Another class of drugs that can interact with HARP6 are called small molecule inhibitors of DNA-protein binding. These drugs work by binding to a specific DNA-protein binding site on a protein and preventing it from binding to DNA. This class of drugs has been shown to be effective in modulating the activity of various proteins, including HARP6.

In conclusion, HARP6 is a protein that is expressed in various tissues of the human body and has been shown to play a role in several cellular processes that are associated with the development and progression of various diseases. As a potential drug target and biomarker, HARP6 is an attractive target for the development of new pharmaceuticals for a variety of diseases. The development of small molecules that can modulate the activity of HARP6 is an promising strategy for the treatment of these diseases.

Protein Name: Actin Related Protein 6

Functions: Required for formation and/or maintenance of proper nucleolar structure and function (PubMed:26164235). Plays a dual role in the regulation of ribosomal DNA (rDNA) transcription (By similarity). In the presence of high glucose, maintains active rDNA transcription through H2A.Z deposition and under glucose starvation, is required for the repression of rDNA transcription, and this function may be independent of H2A.Z (By similarity)

More Common Targets